Anavex Life Sciences Corp.

NASDAQ:AVXL

Biotechnology

Healthcare
$0.72 -1.67%

-$0.04 today

Market cap
$66.69M
Beta
1.12
P/E (TTM)
-5.9
EPS (TTM)
-$0.45
52W Low $2.41High $13.99

Volume 1.06M

Average 1.39M

AVXL Change in Working Capital

Cash absorbed or released by changes in receivables, inventory, payables, and other operating balances.

Anavex Life Sciences Corp.NASDAQ: AVXL

Change in Working Capital · Q1 FY2026 · quarter ended Dec 2025

Change in working capital growth accelerates

Q1 FY2026 change in working capital of $2.58M (cash outflow) rose 24.9% year over year, ahead of the -383.2% change in trailing-twelve-month change in working capital. Sequentially, it rose 3.2% from the prior quarter.

Context

  • Change in working capital increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +24.9% holds above the trailing-twelve-month pace of -383.2%.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterDec 2025
-$2.58M+3.2% QoQ
Last fiscal yearSep 2025
-$4.22M-253.2% YoY
LTMDec 2025
-$4.73M-383.2% YoY
Change in Working Capital past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+24.9%——
1 year-253.2%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Change in Working Capital history

USD · from the cash flow

Latest · FY2025
(4.22M) USD
Year-over-year change
-253.2%

Change in Working Capital vs competitors

How AVXL compares with its peers on the latest reported figures

  • Peers report in different currencies, so change in working capital is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -383.2% is the lowest of 10, against a peer median of +190.8%.
AVXL Competitors
Change in Working Capital for AVXL and competitors
Company Period LTM YoY 3-year CAGR% of revenue
MGTXMeiraGTx Holdings plcLTM Mar 2026$81.23M USD+190.8%+42.8%101.9%
ARVNArvinas, Inc.LTM Mar 2026$69.5M USD-75.6%+41.4%77.7%
CTMXCytomX Therapeutics, Inc.LTM Mar 2026$29.7M USD-77.6%+30.8%83.6%
VALNValneva SELTM Mar 2026€25.29M EUR+212.0%-90.0%16.2%
ERASErasca, Inc.LTM Sep 2026$12.85M USD+457.1%——
MBXMBX Biosciences, Inc. Common StockLTM Sep 2026$11.65M USD+1978.7%+6.9%—
MLTXMoonLake ImmunotherapeuticsLTM Mar 2026$8.66M USD+762.3%——
RGNXREGENXBIO Inc.LTM Mar 2026$6.13M USD-120.4%-5.5%7.0%
AVXLAnavex Life Sciences Corp.LTM Dec 2025$4.73M USD-383.2%——
ABSIAbsci CorporationLTM Mar 2026$81K USD+108.6%—4.4%
Peer median (excluding AVXL) —+190.8%+18.8%47.0%

Competitors are the stored peer set for AVXL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Sep 2021
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
Net Income(37.91M)(47.98M)(47.51M)(43M)(46.38M)
Depreciation & Amortization00000
Deferred Income Tax00000
Stock-Based Compensation8.23M18.38M16.37M9.44M11.55M
Change in Working Capital(706K)5.36M2.51M2.75M(4.22M)
Accounts Receivables(4.29M)5.94M484K260K1.64M
Inventory00000
Accounts Payables751K(914K)497K5.31M(5.38M)
Other Working Capital2.83M331K1.52M(2.81M)(478K)
Other Non-Cash Items00845K00
Operating Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)
Capital Expenditures00000
Acquisitions (Net)00000
Purchases of Investments00000
Sales of Investments00000
Other Investing Activities00000
Investing Cash Flow00000
Debt Repayment00000
Common Stock Issued153.22M22M29.65M11.98M12.14M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities24K(707K)29.65M11.98M(2.71M)
Financing Cash Flow153.24M21.29M29.65M11.98M9.43M
Effect of Forex Changes00000
Net Change in Cash122.86M(2.95M)1.87M(18.84M)(29.61M)
Free Cash Flow(30.38M)(24.24M)(27.79M)(30.81M)(39.04M)

Anavex Life Sciences Corp.

NASDAQ:AVXL

Intrinsic Alpha fair value

Locked

Current Price

$0.72

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.